focus -WSS

focus

author：entertainment 2025-09-06 02:04:38 - browse：3742

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Ending health disparities requires full federal government, panel says

focus

Wikipedia

WSS

Texas Medical Board asked to define abortion emergency exception

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Interest rates are at a 22

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

The Biogen Aduhelm mess could happen again

Marc Tessier

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The CDC's new social media misinformation war

Psychedelics group wrestles with new pharma identity

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

Medicare proposal to cover medical devices draws a mixed reaction

CDC: Cases of alpha

The high cost of giving birth even with insurance

What’s missing from the debate over nursing home staff minimums

Trump demands the U.S. pay no more for drugs than other countries … again

Unique patient identifier: Experts argue the benefits, pitfalls

leisure time

VC firm RA Capital starts a new synthetic biology incubator

Padmanee Sharma of MD Anderson at center of lawsuit over credit

An outrageous hospital charge: I paid $710 for an hour of babysitting

Unique patient identifier: Experts argue the benefits, pitfalls

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Timeline: Special counsel's probe into Trump's handling of classified documents

knowledge

focus

Wikipedia

knowledge